上海市免疫治疗创新研究院（以下简称“研究院”）系于2021年经上海市人民政府批准设立，由上海市人民政府和上海交通大学共同建设。研究院面向“健康中国”战略，由国际著名免疫学家、中国科学院院士董晨教授领衔，依托上海交通大学医学院及其附属仁济医院进行系统性建设，整合上海交通大学医学院和仁济医院在免疫学基础研究和临床免疫的学科优势及丰富的临床资源优势，深度融入张江、临港国家实验室整体发展布局，以免疫学相关基础和应用基础研究为切入点，聚焦肿瘤免疫治疗、慢性炎症疾病与移植免疫、传染性疾病与疫苗等重点研发方向和应用领域，努力建设成为具有全球影响力的免疫创新策源地、免疫学领域的高端和关键人才的引育基地、国际一流的免疫学基础创新到产业应用的转化基地。

Shanghai Immune Therapy Institute (SITI), approved by Shanghai Municipal People’s Government, is jointly established and run by Shanghai Jiao Tong University School of Medicine (SJTUSM) and its affiliated Renji Hospital under the leadership of Dr. DONG Chen, world famous immunologist and Academician of the Chinese Academy of Sciences. SITI will gather advantages of both SJTUSM and Renji Hospital in basic and clinical advantages in immunology and integrate itself into the overall development outlook of State key laboratories in the Zhangjiang National Innovation Demonstration Zone and the Lingang free trade area in Pudong New District. Tumor immunotherapy, chronic inflammatory diseases and transplantation immunology, and infectious diseases and vaccines are the three major R&D and application areas for our institute.